Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to ...

As required by law, Axsome and Hikma will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review. Similar patent litigation brought by ...

Axsome Therapeutics (NASDAQ:AXSM) announced Wednesday a settlement agreement with U.K.-based Hikma Pharmaceuticals ...

Total revenues in the fourth quarter consisted of product revenues from Auvelity and Sunosi (solriamfetol) and royalty revenues. Net product revenues were $117.3 million in the quarter compared ...

Sunosi net product revenues were $26.2 million and $94.3 million for the fourth quarter and full year of 2024, representing 16% and 26% year-over-year growth, respectively, which consisted of $24. ...

The quarter was marked by strong sales from its commercial products, Auvelity and Sunosi, and heightened strategic investment in research and development (R&D) reflected in increased spending.

The company currently markets Auvelity (AXS-05) for treating major depressive disorder (MDD) and Sunosi (solriamfetol) for treating narcolepsy. Auvelity was launched in the United States in 2022 ...

Axsome Therapeutics (AXSM) announced that it has entered into a settlement agreement with Hikma Pharmaceuticals (HKMPF), resolving patent ...

Approximately 49,000 prescriptions were written for Sunosi in the U.S. in the fourth quarter of 2024, representing an increase of 16% compared to the same period in 2023, and an increase of 4% ...

NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...